The kidney in Fabry's disease

Clinical Genetics

Volumn 86, Issue 4, 2014, Pages 301-309

  Pisani, Antonio ^a   Visciano, B ^a   Imbriaco, M ^a   Di Nuzzi, A ^a   Mancini, A ^a   Marchetiello, C ^a   Riccio, E ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Chronic kidney disease; Enzyme replacement therapy; Fabry disease; Fabry nephropathy

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; GLYCOSPHINGOLIPID;

CLINICAL EFFECTIVENESS; DISEASE COURSE; DISEASE SEVERITY; ELECTRON MICROSCOPY; ENZYME REPLACEMENT; FABRY DISEASE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; INCIDENCE; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; OUTCOME ASSESSMENT; PHENOTYPE; PREVALENCE; REVIEW; ULTRASTRUCTURE; COMPLICATION; GENETICS; KIDNEY; METABOLISM; PATHOLOGY; RENAL INSUFFICIENCY, CHRONIC;

ALPHA-GALACTOSIDASE; DISEASE PROGRESSION; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; GLYCOSPHINGOLIPIDS; HUMANS; KIDNEY; RENAL INSUFFICIENCY, CHRONIC;

EID: 84908236154     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12386     Document Type: Review

References (91)

1. Desnick RJ, Brady R, Barranger J et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003: 138: 338-346.
2. Nakao S, Takenaka T, Maeda M et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995: 333: 288-293.
3. Mehta A, Ricci R, Widmer U et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004: 34: 236-242.
4. NagaoY, Nakashima H, FukuharaYet al. Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of a-galactosidase A. Clin Genet 1991: 39: 233-237.
5. Branton MH, Schiffmann R, Sabnis SG et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002: 81: 122-138.
6. Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B; Fabry registry. Cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 2008: 23: 1600-1607.
7. Schiffmann R, Warnock DG, Banikazemi M et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009: 24: 2102-2111.
8. Pisani A, Visciano B, Roux GD et al. Enzyme replacement therapy in patients with Fabry disease: state of the arte and review of the literature. J Inherit Metab 2012: 107: 267-275.
9. Germain DP. Fabry disease. Orphanet J Rare Dis 2010: 5: 30.
10. Linthorst GE, Vedder AC, Aerts JM, Hollak CE. Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta 2005: 353: 201-203.
11. Mignani R, Ferriozzi S, Schaefer RM et al. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy. Clin J Am Soc Nephrol 2010: 5: 379-385.
12. Tsakiris D, Simpson HK, Jones EH et al. Report on management of renal failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 1996: 11: 4-20.
13. Thadhani R, Wolf M, West ML et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002: 61: 249-255.
14. Nakao S, Kodama C, Takenaka T et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003: 64: 801-807.
15. Kotanko P, Kramar R, Devrnja D et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 2004: 15: 1323-1329.
16. Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE. Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet 2010: 47: 217-222.
17. Desnick RJ, Ioannou Y, Eng CM. Fabry disease: a-galactosidase A deficiency. In: Scriver CH, Beaudet AL, Sly WS, et al., eds. The metabolic and molecular bases of inherited disease. New York, NY: Mc Graw Hill, 1995: 2741-2784.
18. Pisani A, Imbriaco M, Zizzo C et al. A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report. BMC Cardiovasc Disord 2012: 8: 12-39.
19. AltarescuGM, Goldfarb LG, ParkKYet al. Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease. Clin Genet 2001: 60: 46-51.
20. Meroni M, Sessa A, Battini G, Tazzari S, Torri Tarelli L. Kidney involvement in Anderson-Fabry disease. Contrib Nephrol 1997: 122: 178-184.
21. Najafian B, Svarstad E, Bostad L et al. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int 2011: 79: 663-670.
22. Faraggiana T, Churg J, Grishman E. Light- and electron-microscopic histochemistry of Fabry's disease. Am J Pathol 1981: 103: 247-262.
23. Valbuena C, Carvalho E, BustorffM et al. Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy. Virchows Arch 2008: 453: 329-338 Erratum in: Virchows Arch, 2009; 454: 721-722.
24. Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R. Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int 1978: 13: 223-235.
25. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol 2002: 13: 134-138.
26. Sessa A, Tosoni A, Nebuloni M et al. Renal ultrastructural findings in Anderson- Fabry disease. J Nephrol 2002: 15: 109-112.
27. Grunfeld JP, Noel LH. Atteinte renale de la maladie de Fabry: resultats de l'enzymotherapie. Med Sci 2005: 21: 23-25.
28. Bracamonte ER, Kowalewska J, Starr J, Gitomer J, Alpers CE. Iatrogenic phospholipidosis mimicking Fabry disease. Am J Kidney Dis 2006: 48: 844-850.
29. Muller-Hocker J, Schmid H, Weiss M, Dendorfer U, Braun GS. Chloroquine induced phospholipidosisof the kidneymimicking Fabry's disease: case report and review of the literature. Hum Pathol 2003: 34: 285-289.
30. Noel LH, Laurent B, Grunfeld JP. Renal biopsies in Fabry disease: a multicenter French study. Nephrol Ther 2012: 8: 433-438.
31. Desnick RJ, Dawson G, Desnick SJ, Sweeley CC, Krivit W. Diagnosis of glycosphingolipidoses by urinary-sediment analysis. N Engl J Med 1971: 284: 739-744.
32. Nagao S, Satoh N, Inaba S, Iijima S. Concentric lamellar spheres in urine from a female carrier of and patients with Fabry's disease - with special reference to polarization and electron microscopic comparison with nephrotic syndrome. J Dermatol 1985: 12: 70-78.
33. Chatterjee S, Gupta P, Pyeritz RE, Kwiterovich PO Jr. Immunohistochemical localization of glycosphingolipid in urinary renal tubular cells in Fabry's disease. Am J Clin Pathol 1984: 82: 24-28.
34. Utsumi K, Mitsuhashi F, Asahi K et al. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments. Clin Chim Acta 2005: 360: 103-107.
35. Barr C, Clarke JT, Ntwari A, Drouin R, Auray-Blais C. Fabry disease urinary globotriaosylceramide/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6 months. Mol Genet Metab 2009: 97: 278-283.
36. Auray-Blais C, Cyr D, Ntwari A et al. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol Genet Metab 2008: 93: 331-340.
37. Young E, Mills K, Morris P et al. Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr Suppl 2005: 94: 51-54.
38. Cuccurullo M, Beneduci A, Anand S et al. Fabry disease: perspectives of urinary proteomics. J Nephrol 2010: 23: 199-212.
39. Wanner C, Oliveira JP, Ortiz A et al. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol 2010: 5: 2220-2228.
40. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006: 116: 288-296.
41. Taal MW, Brenner BM. Predicting initiation and progression of chronic kidney disease: developing renal risk scores. Kidney Int 2006: 70: 1694-1705.
42. Eng CM, Germain DP, Banikazemi M et al. Fabry disease: guidelines for the evaluation and management of multiorgan system involvement. Genet Med 2006: 8: 539-548.
43. Kleinert J, Dehout F, Schwarting A et al. Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens 2006: 19 (8): 782-787.
44. Sakuraba H, Murata-Ohsawa M, Kawashima I et al. Comparison of the effects of agalsidase alpha and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet 2006: 51: 180-188.
45. Lee K, Jin X, Zhang K et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003: 13: 305-313.
46. Banikazemi M, Bultas J, Waldek S et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007: 146: 77-86.
47. Schiffmann R, Murray GJ, Treco D et al. Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci 2000: 97: 365-370.
48. European Medicines Agency. Fabrazyme®-summary of product characteristics, from http://www.emea.europa.eu/humandocs/Humans/EPAR/fabrazyme/fabrazyme.htm. Accessed on September 30, 2009.
49. European Medicines Agency. Replagal®-summary of product characteristics, from http://www.emea.europa.eu/humandocs/Humans/EPAR/replagal/replagal.htm. Accessed on September 30, 2009.
50. El Dib RP, Nascimento P, Pastores GM. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2013: 2: -CD006663.
51. Schiffmann R, Kopp JB, Austin HA 3rd et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA2001: 285: 2743-2749.
52. Mehta A, Beck M, Elliott P et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009: 374: 1986-1996.
53. West M, Nicholls K, Mehta A et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009: 20: 1132-1139.
54. Feriozzi S, Torras J, Cybulla M et al. The effectiveness of long-term agalsidase alpha therapy in the treatment of Fabry nephropathy. Clin J Am Soc Nephrol 2012: 7: 60-69.
55. Mehta A, Beck M, Eyskens F et al. Fabry disease: a review of current management strategies. QJM 2010: 103: 641-659.
56. Eto Y, Ohashi T, Utsunomiya Y et al. Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study. J Inherit Metab Dis 2005: 28: 575-583.
57. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 2006: 69: 1216-1221.
58. Germain DP, Waldek S, Banikazemi M et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007: 18: 1547-1557.
59. Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 2007: 18: 2609-2617.
60. Warnock DG, Ortiz A, Mauer M et al. Nephrol Dial Transplant 2012: 27: 1042-1049.
61. Fogo AB, Bostad L, Svarstad E et al., all members of the International Study Group of Fabry Nephropathy (ISGFN). Scoring system for renal pathology in Fabry disease: Report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 2010: 25: 2168-2177.
62. Whitfield P, Calvin J, Hogg S et al. Monitoring enzyme replacement therapy in Fabry disease - role of urine globotriaosylceramide. J Inherit Metab Dis 2005: 28: 21-33.
63. Tøndel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 2008: 51: 767-776 Erratum in: Am J Kid Dis, 2009; 53: 567.
64. Lubanda JC, Anijalg E, Bzdúch V, Thurberg BL, Bénichou B, Tylki-Syzmanska A. Evaluation of a lowdose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease. Genet Med 2009: 11: 256-264.
65. Tondel C, Bostad L, Kampevold Larsen K et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 2013: 24: 137-148.
66. Kleinert J, Lorenz M, Hauser AC et al. Measurement of renal function in patients with Fabry disease. Acta Paediatr Suppl 2005: 94: 19-23.
67. Feriozzi S, Germain DP, Di Vito R, Legrand A, Ricci R, Barbey F. Cystatin C as a marker of early changes of renal function in Fabry nephropathy. J Nephrol 2007: 20: 437-443.
68. Rombach SM, Baas MC, ten Berge IJ, Krediet RT, Bremelman FJ, Hollak CE. The value of estimated GFR in comparison to measured GFR for the assessment of renal function in adult patientswith Fabry disease. Nephrol Dial Transplant 2010: 25: 2549-2556.
69. Moore DF, Krokhin OV, Bravis RC et al. Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities. Proc Natl Acad Sci USA 2007: 104: 2873-2878.
70. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001: 357: 1601-1608.
71. Batista EC, Carvalho LR, Casarini DE et al. ACE activity is modulated by the enzyme α-galactosidase A. J Mol Med 2010: 89: 65-74.
72. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009: 1-130.
73. Agarwal R. Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD. Clin J Am Soc Nephrol 2009: 4: 1523-1528.
74. de Zeeuw D, Agarwal R, Amdahl M et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010: 376: 1543-1551.
75. Sanchez-Niño MD, Sanz AB, Carrasco S et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant 2011: 26: 1797-1802.
76. Ortiz A, Cianciaruso B, Cizmarik M et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant 2010: 25: 769-775.
77. Pastores GM, Boyd E, Crandall K, Whelan A, Piersall L, Barnett N. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease. Nephrol Dial Transplant 2007: 22: 1920-1925.
78. Kosch M, Koch HG, Oliveira JP et al. Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease. Kidney Int 2004: 66: 1279-1282.
79. Pisani A, Spinelli L, Sabbatini M et al. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. Am J Kidney Dis 2005: 46: 120-127.
80. Mignani R, Feriozzi S, Pisani A et al. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. Nephrol Dial Transplant 2008: 23: 1628-1635.
81. Sozio SM, Armstrong PA, Coresh J et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis 2009: 54: 468-477.
82. Weidemann F, Niemann M, Breunig F et al. Longterm effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009: 119: 524-529.
83. Mignani R, Panichi V, Giudicissi A et al. Kidney Int 2004: 65: 1381-1385.
84. Cybulla M, Walter KN, Schwarting A et al. Kidney transplantation in patients with Fabry disease. Transpl Int 2009: 22: 475-481.
85. Mignani R, Gerra D, Maldini L et al. Long-term survival of patients with renal transplantation in Fabry's disease. Contrib Nephrol. 2001: 136: 229-233.
86. Clarke JTR, Guttmann RD, Wolfe LS, Beaudoin JG, Morehouse DD. Enzyme replacement therapy by renal allotransplantation in Fabry's disease. New Engl J Med 1972: 287: 1215-1218.
87. Wutrich RP, Weinreich T, Binswanger U, Gloor HJ, Candinas D, Hailemariam S. Should living related kidney transplantation be considered for patients with renal failure due to Fabry's disease? Nephrol Dial Transplant 1998: 13: 2934-2936.
88. Desnik RJ, Banikazemi M, Wassertein M. Enzyme replacement therapy in Fabry's disease, an inherited nephropathy. Clin Nephrol 2002: 57: 1-8.
89. Mosnier JF, Degott C, Bedrossian J et al. Recurrence of Fabry's disease in a renal allograft eleven years after successful renal transplantation. Transplantation 1991: 51: 759-762.
90. Peces R. Is there true recurrence of Fabry's disease in the transplanted kidney? Nephrol Dial Transplant 1996: 11: 561.
91. Feriozzi S, Schwarting A, Sunder-Plassmann G, West M, Cybulla M. Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am. J. Nephrol 2009: 29 (5): 353-361.